Member Info for MRK2020

In short yes, I do see it going above $1 again. When, who knows, but I'm interested to see what the board do as they actively manage the company with a view to regaining the NASDAQ minimum of $1 to avoid delisting. Meanwhile the MS clinical uses seem to be going well, but where on earth are any of the promised trials!

I was listening while working. It was led by Howard Weiner. A few different clinicians came on to summarize data from the first MS patient. The indications were all positive, and above expectations. And well tolerated etc. The patient had a six week pause from drugs and they noted a decline in this period. They have now initiated a second patient as of January. Weiner noted some positive effects were reported by his doctor already. So, they were very bullish on data thus far. They plan to seek permission for other patients over next year. Outcomes to be reported for both patients in fall or earlier if available. Trial to follow .. likely up to 100 patients. Alzheimer's and ALS...I think are the other conditions they want to target...but that's way off.
So, in summary, it was a positive update re the data from one patient. So caveats apply. Rightly or wrongly It was not shareholder focussed, but clinical focussed.

better...

Yep.. nothing to worry about here. Holding strong here.

Added my donation today. A nice thing to do.
GLA

plus the longer research piece, which I found pretty helpful
https://www.proactiveinvestors.co.uk/companies/news/960997/controlling-disease-using-a-safe-nasal-and-oral-antibody-960997.html/long

Hi Dunk - in general that's right, but there were/are opportunities to speed up various regulatory stages of the trial and indeed to invest in treatments. Compared to investment/focus on vaccines and test and trace etc, the government focus on treatments is (or seems) negligible. Take the recent TILS application for inclusion in the therapies trial for example...not exactly fast track and why wasn't this progressed immediately after the Brazil trial anyway.

hi all - would be interested in views following the update.
Decent progress in lieu of the the product range, sales, expansion capacity and progress to sustainability, but Covid and exchange rates have impacted and of course there is ongoing uncertainty with regard to the former.
Just wondered if there were any particular points in the update that caught people's eyes (good or not so good)

and I'd like a bit of whatever ISATony was drinking...

Just got around to watching presentation - totally on board with Phase 2 expansion plans - got to prove the demand is there first and get toward the 30million extra sales which Phase 1 provides. They have reduced the expected cost of Phase 2 I note also. Onwards and upwards (towards Mr/Ms Tony's SP)

Thanks for replies..
I understand the wait and see approach, but I would have been happier if the board had the confidence to say they would instigate Phase 2 as soon as [whatever their criteria was] rather than place on back burner with the no plans in short or medium term. Investors would have wanted to know that the forecasted demand was there...and £4million was allocated to the Phase 2 expansion.

If cash burn based on last 6 months is circa 420k and they have £6.6 million minus £4million for expansion then we have £2.6 million available (which would last about 6 months). Of course, we anticipate increasing sales in this period (Hardman analyst talked of 30% uplift in H2) and the cash burn should drop each month. So I think we can reach profitability whilst maintaining the money for Phase 2 expansion which is good.

Also...From June 2020 RNS, £1.1. million was allocated to the Phase 1 expansion and would take 6 months. But they report it cost £2.1 million and RNS' show that it took a year (initiated June 2020, completion RNS 28 June 2021).
Curious - why do they report repeatedly that it was on budget (and on time) - with their own figures showing it cost twice as much and took twice as long (lol!). Sorry - I should have asked TRX in investor meet...but didn't make it.

RNS from June 2020...
'The Directors intend to use the net proceeds of the Fundraise as follows with approximately:
· £1.1 million towards the first phase of the Group's expansion programme to increase the manufacturing capacity in San Antonio to sustain future business growth, and general capital expenditure;
· £4.0 million towards the second phase of the Group's expansion programme to increase the manufacturing capacity in San Antonio to sustain future business growth;
· £1.9 million towards R&D and clinical, generating further clinical and health economic real-world data to support brand differentiation of dCELL® and BioRinse™ from competitive products; and
· £5.0 million towards general working capital to support the Company's growth.
It is envisaged that the first phase of the expansion programme will entail the addition of two sterile packaging clean rooms in the existing facility over a six month period. Once fully operational, these additional clean rooms are expected to increase the Group's current BioRinse processing capacity by c.50% and thereby significantly increase the maximum serviceable revenue for the BioRinse product portfolio. It is envisaged that phase two of the expansion programme will entail a further potential ten clean rooms, in the new facility adjacent to the current manufacturing site, expected to take approximately 12 months to complete. The Company intends to bring this new capacity on stream in a managed process to meet demand. Once fully operational, it is expected that this completed expansion programme will increase the Company's revenue generation potential by up to c.$36m per year'

Very happy re cost cutting while expanding. Running a tight ship, which is absolutely what is needed.
In a very good position now going forward to profitability. My only slight disappointment was re Phase 2 expansion - i.e. the implication that this is not needed in the short term (why not?). Was there any discussion of this in the investor talk? (which I will watch if it is available anywhere for a rerun?)
thanks

Re: results out tomorrow:
company investor webinar at 4.30pm - sign up at Investor meeet https://www.investormeetcompany.com/
the last one was really good.
RE questions - anyone know if you need to submit in advance? (if so, how) or can you do it live?

Seems to just be the same pattern repeated over last 6 months - i.e. in the same range on lowish volume
I'm hopeful that the update causes a breakout on positive news but we shall know soon enough.

Given the Brazil trial results it is an international disgrace that not a single patient anywhere in the world has had a dose of Foralumab as a Covid treatment in 10 months- how many lives could have been saved! It's beyond comprehension that there was no clamour for further trials. Why are TILS even having to pay for the next trial - surely there should be grants for this sort of thing. How much money has been wasted on ineffective Innova LFTs and track and trace? I remain dumbfounded over this point. (it's not just in relation to TILS/Foralumab btw)

oh - it's already happened. did anyone go? would welcome a summary if anything new.

Its interesting that the SP is the same as 6 months ago.
I guess we need to see more/continued evidence that TRX is moving to profitability in the upcoming results, given there is not a huge amount of leeway re the cash runway.

wasnt' just google...was on HL also. went down 52%
stop loss raid? did anyone get caught out..hope not!
still, we all knew this could fly at any time, but was kinda banking on up :-)

We are pretty much at the prediction target I made last year for October, in the charity guess the share price game, but with the Phase 1 expansion having been delivered on time and on budget, and the new products, I'm very excited about this company prospects. More so than any other in my portfolio. Topped up today; as thinking we may see a rise into interims, or indeed subsequently - towards G&M target. Fingers crossed anyway. GLA

nice to see some relatively decent buys coming through...
need some positive news to sustain and build on the rise.
Plenty in the pipeline but timetable's slipping!
come along TILS

should have added the link to the hardman reports - https://www.hardmanandco.com/research/corporate-research/poised-for-growth/
While these are not independent, they do cover the fundamentals and the history.